pCDCAR5 CD44 h(28ζ, PD1)(CAR-LC372)
The vector of anti-CD44 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD44. The T cells are genetically modified through transduction with a retroviral vector expressing scFv of anti-CD44 antibody linked to PD-1, CD28 and CD3ζ signaling domains. The incorporation of PD-1 will reduce the immunosuppressive activity on CAR-T cells. And the vector product was designed for the treatment of breast cancer and prostate cancer.
Details
Targeting Cell Type
T cell
Targeting Diseases
Breast cancer, Prostate cancer
Receptor Construction
scFv-PD1-CD28-CD3ζ
Discription of Signaling Cassetes
CD28
CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide co-stimulatory signals required for T cell activation and survival. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells (APC). CD28 modulates the primary TCR/CD3ζ signal in a different fashion than the late costimulatory elements OX40 and 4-1BB. CD28 enhances the expression of downstream regulators that impact on T-cell proliferation, death, differentiation, and effector functions. CAR+ T cells containing the CD28 endodomain showed strikingly enhanced sustained T cell activation, growth, survival. And CD28 results in a brightly expressed, stable receptor as the transmembrane domain. Including CD28 costimulatory domains in CARs led to enhanced anti-malignancy efficacy.
CD3ζ
CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.
Target
Gene Name
CD44 molecule (Indian blood group)
Synonyms
IN; LHR; MC56; MDU2; MDU3; MIC4; Pgp1; CDW44; CSPG8; HCELL; HUTCH-I; ECMR-III
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Related Products
| Cat# |
Description |
| OAdCmodV-YX0331 |
Oncolytic Adenovirus (Capsid modified Ad5, phTERT-Δ24/55k, Anti-CD44-2), Viral particle |
| OAdCmodV-YX0324 |
Oncolytic Adenovirus (Capsid modified Ad5, phTERT-Δ55k, Anti-CD44-3), Viral particle |
| OAdCmodV-YX0325 |
Oncolytic Adenovirus (Capsid modified Ad5, phTERT-Δ24/19k, Anti-CD44), Viral particle |
| OAdCmodV-YX0322 |
Oncolytic Adenovirus (Capsid modified Ad5, phTERT-Δ55k, Anti-CD44-1), Viral particle |
| OAdCmodV-YX0315 |
Oncolytic Adenovirus (Capsid modified Ad5, pCMV-Δ24/55k, Anti-CD44-2), Viral particle |
| OAdCmodV-YX0306 |
Oncolytic Adenovirus (Capsid modified Ad5, pCMV-Δ55k, Anti-CD44-1), Viral particle |
| OAdCmodV-YX0317 |
Oncolytic Adenovirus (Capsid modified Ad5, pCMV-Δ19k, Anti-CD44), Viral particle |
| CAR-LC226 |
Anti-CD44 h(CD28-CD3ζ) CAR, pCDCAR1 |
| OAdCmodV-YX0313 |
Oncolytic Adenovirus (Capsid modified Ad5, pCMV-Δ24/55k, Anti-CD44), Viral particle |
| OAdCmodV-YX0336 |
Oncolytic Adenovirus (Capsid modified Ad5, phTERT-Δ19k, Anti-CD44-3), Viral particle |
Oncolytic VirusCarcinoma
Kits for CARs/TCRs Development 
Datasheet
Subscribe to Our Newsletter for Updates: